Diffuse large B-cell lymphoma - Treatment approaches in the molecular era

Nature Reviews Clinical Oncology

Volumn 11, Issue 1, 2014, Pages 12-23

  Roschewski, Mark ^a   Staudt, Louis M ^a   Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 199; ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DACTOLISIB; DOXORUBICIN; E 7438; ENZASTAURIN; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; I KAPPA B KINASE INHIBITOR; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIDILIZUMAB; PREDNISONE; PROTEIN BCL 6; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C BETA INHIBITOR; RITUXIMAB; STAT PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG TARGETING; HUMAN; LARGE CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DELIVERY SYSTEM; EVIDENCE BASED MEDICINE; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN;

EID: 84891001835     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.197     Document Type: Review

References (150)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Armitage, J. O. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin. Proc. 87, 161-171 (2012).
3. Friedberg, J. W. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011, 498-505 (2011).
4. Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184-4190 (2010).
5. DeVita, V. T. Jr et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1, 248-250 (1975).
6. Fisher, R. I. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328, 1002-1006 (1993).
7. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
8. Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-391 (2006).
9. Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116, 2040-2045 (2010).
10. Pfreundschuh, M. et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12, 1013-1022 (2011).
11. Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large b-cell lymphoma. J. Clin. Oncol. 26, 4587-4594 (2008).
12. Schmitz, N. et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 13, 1250-1259 (2012).
13. Cunningham, D. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381, 1817-1826 (2013).
14. Récher, C. et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378, 1858-1867 (2011).
15. Wilson, W. H. et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97, 758-765 (2012).
16. Dunleavy, K. et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 368, 1408-1416 (2013).
17. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00118209 (2013).
18. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
19. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
20. Lenz, G. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA 105, 13520-13525 (2008).
21. Wright, G. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100, 9991-9996 (2003).
22. Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862 (2003).
23. Steinhardt, J. J. & Gartenhaus, R. B. Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions. Clin. Cancer Res. 18, 4538-4548 (2012).
24. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
25. Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879-3884 (2012).
26. Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398-1403 (2013).
27. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
28. [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 329, 987-994 (1993).
29. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313-2323 (2008).
30. Savage, K. J. et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114, 3533-3537 (2009).
31. Jaffe, E. S. & Pittaluga, S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am. Soc. Hematol. Educ. Program 2011, 506-514 (2011).
32. Johnson, N. A. et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114, 2273-2279 (2009).
33. Aukema, S. M. et al. Double-hit B-cell lymphomas. Blood 117, 2319-2331 (2011).
34. Snuderl, M. et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 34, 327-340 (2010).
35. Dunleavy, K. et al. MYC+ aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R [abstract]. Ann. Oncol. 22 (Suppl. 4), a071 (2011).
36. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01092182 (2013).
37. Cuccuini, W. et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by followed by BEAM plus autologous stem cell transplantation. Blood 119, 4619-4624 (2012).
38. Green, T. M. et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3460-3467 (2012).
39. Johnson, N. A. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452-3459 (2012).
40. Hu, S. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121, 4021-4031 (2013).
41. Horn, H. et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121, 2253-2263 (2013).
42. Thieblemont, C. et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J. Clin. Oncol. 29, 4079-4087 (2011).
43. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
44. Kirmizis, A. et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18, 1592-1605 (2004).
45. Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011).
46. Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
47. Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
48. Velichutina, I. et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116, 5247-5255 (2010).
49. Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
50. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
51. Qi, W. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109, 21360-21365 (2012).
52. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01897571 (2013).
53. Pfeifer, M. et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 12420-12425 (2013).
54. Siebert, R. et al. Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1? Blood 92, 4487-4489 (1998).
55. Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153 (2013).
56. Lannutti, B. J. et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594 (2011).
57. Furman, R. R. et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood 116, a55 (2010).
58. Smith, S. M. et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J. Clin. Oncol. 28, 4740-4746 (2010).
59. Witzig, T. E. et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25, 341-347 (2011).
60. Petrich, A. M. et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin. Cancer Res. 18, 2534-2544 (2012).
61. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01466868 (2013).
62. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01481129 (2013).
63. Iqbal, J. et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am. J. Pathol. 165, 159-166 (2004).
64. Schuetz, J. M. et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26, 1383-1390 (2012).
65. Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149-1159 (2010).
66. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
67. Davids, M. S. et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study [abstract]. Blood 120, a304 (2012).
68. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01594229 (2013).
69. Phan, R. T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004).
70. Basso, K. & Dalla-Favera, R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv. Immunol. 105, 193-210 (2010).
71. Cerchietti, L. C. et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397-3405 (2009).
72. Cerchietti, L. C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400-411 (2010).
73. Rawlings, D. J., Schwartz, M. A., Jackson, S. W. & Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12, 282-294 (2012).
74. Lim, K. H., Yang, Y. & Staudt, L. M. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol. Rev. 246, 359-378 (2012).
75. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
76. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717-721 (2009).
77. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
78. Rui, L., Schmitz, R., Ceribelli, M. & Staudt, L. M. Malignant pirates of the immune system. Nat. Immunol. 12, 933-940 (2011).
79. Rawlings, D. J., Sommer, K. & Moreno-García, M. E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat. Rev. Immunol. 6, 799-812 (2006).
80. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679 (2008).
81. Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
82. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
83. Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712-716 (2009).
84. Lam, L. T. et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 11, 28-40 (2005).
85. Strauss, S. J. et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 67, 2783-2790 (2007).
86. Dunleavy, K. et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113, 6069-6076 (2009).
87. Ruan, J. et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 690-697 (2011).
88. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00931918 (2013).
89. Gu, J. J. et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br. J. Haematol. 162, 657-669 (2013).
90. Dasmahapatra, G. et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115, 4478-4487 (2010).
91. Dasmahapatra, G. et al. The irreversible proteasome inhibitor carfilzomib interacts synergistically with the selective HDAC6 inhibitor ACY1215 in ABC-and GC-DLBCL and mantle cell lymphoma sensitive or resistant to bortezomib [abstract]. Blood 120, a2765 (2012).
92. Dasmahapatra, G. et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol. Cancer Ther. 11, 1122-1132 (2012).
93. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01276717 (2013).
94. Tageja, N. Lenalidomide -current understanding of mechanistic properties. Anticancer Agents Med. Chem. 11, 315-326 (2011).
95. Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723-737 (2012).
96. Zhang, L. H. et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J. Haematol. 160, 487-502 (2012).
97. Hernandez-Ilizaliturri, F. J. et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117, 5058-5066 (2011).
98. Dal Porto, J. M. et al. B cell antigen receptor signaling 101. Mol. Immunol. 41, 599-613 (2004).
99. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573-586 (2009).
100. Gauld, S. B., Dal Porto, J. M. & Cambier, J. C. B cell antigen receptor signaling: roles in cell development and disease. Science 296, 1641-1642 (2002).
101. Young, R. M. & Staudt, L. M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 12, 229-243 (2013).
102. Winer, E. S., Ingham, R. R. & Castillo, J. J. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 21, 355-361 (2012).
103. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
104. Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723-737 (2012).
105. Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88-94 (2013).
106. Wilson, W. H. et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood 120, a686 (2012).
107. Younes, A. et al. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) [abstract]. J. Clin. Oncol. 31, a8502 (2013).
108. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01855750 (2013).
109. Saijo, K. et al. Protein kinase C β controls nuclear factor κB activation in B cells through selective regulation of the IκB kinase α. J. Exp. Med. 195, 1647-1652 (2002).
110. Kim, S. W. et al. Protein kinase C-associated kinase is required for NF-κB signaling and survival in diffuse large B-cell lymphoma cells. Blood 111, 1644-1653 (2008).
111. Robertson, M. J. et al. Phase II study of enzastaurin, a protein kinase C β inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 1741-1746 (2007).
112. Hainsworth, J. D. et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) - preliminary analysis [abstract]. Ann. Oncol. 22 (Suppl. 4), a074 (2011).
113. Naylor, T. L. et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 71, 2643-2653 (2011).
114. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01402440 (2013).
115. Ferch, U. et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 206, 2313-2320 (2009).
116. Hailfinger, S. et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 106, 19946-19951 (2009).
117. McAllister-Lucas, L. M., Baens, M. & Lucas, P. C. MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin. Cancer Res. 17, 6623-6631 (2011).
118. Fontan, L. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22, 812-824 (2012).
119. Nagel, D. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825-837 (2012).
120. Young, R. M. & Staudt, L. M. A new "brew" of MALT1 inhibitors. Cancer Cell 22, 706-707 (2012).
121. Lam, L. T. et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111, 3701-3713 (2008).
122. Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515-1523 (2008).
123. Scuto, A. et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 71, 3182-3188 (2011).
124. Mascarenhas, J. & Hoffman, R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 18, 3008-3014 (2012).
125. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01431209 (2013).
126. Younes, A. et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30, 4161-4167 (2012).
127. Grant, C. et al. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr. Hematol. Malig. Rep. 6, 157-163 (2011).
128. Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879 (2003).
129. Eberle, F. C. et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96, 558-566 (2011).
130. Isaacson, P. G., Norton, A. J. & Addis, B. J. The human thymus contains a novel population of B lymphocytes. Lancet 2, 1488-1491 (1987).
131. Steidl, C. & Gascoyne, R. D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118, 2659-2669 (2011).
132. Lenz, G. & Staudt, L. M. Aggressive lymphomas. N. Engl. J. Med. 362, 1417-1429 (2010).
133. Feuerhake, F. et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106, 1392-1399 (2005).
134. Guiter, C. et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 104, 543-549 (2004).
135. Joos, S. et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87, 1571-1578 (1996).
136. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
137. Rui, L. et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18, 590-605 (2010).
138. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
139. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
140. Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19, 3462-3473 (2013).
141. Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381 (2011).
142. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
143. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
144. Rounbehler, R. J. et al. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell 150, 563-574 (2012).
145. Lim, K.-H., Romero, D. L., Chaudhary, D., Robinson, S. D. & Staudt, L. M. IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma [abstract]. Blood 120, a62 (2012).
146. Walsh, K. et al. PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin. Cancer Res. 19, 1106-1115 (2013).
147. Han, S. S. et al. NF-κB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol. Cancer 9, 97 (2010).
148. Shortt, J. et al. Combined inhibition of PI3K-related DNA-damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 121, 2964-2974 (2013).
149. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
150. Hernandez-Ilizaliturri, F. J. et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117, 5058-5066 (2011).